Member Info for badeli

I have attached below (apologies CF73 for not asking permission first!) a post which is now a week old and which summarises what LTHs are expecting imminently - there has been a recent hint that imminent is the correct word but that does not necessarily mean tomorrow or even this week although I am fairly confident that it does. Finally we are expecting to see the numbers published which we have known in general terms for some time but which are still not known across the market. When they are I have no doubt the real value of the company will begin to be reflected in the shareprice. The clock is ticking and I hope is finally at one minute to midnight! Read the posts from the last three weeks, go back through the RNSs and you will understand why I and others in the know, or at least as much as PIs can ever be in the know, are very excited about the coming weeks and months.CF73's post: News due in the coming weeks,- Shareholder Agreement Term Sheet, where equity stakes in our Billion$$$ project are confirmed. Each time I think about it, it feels an even bigger a deal, this.- Historic Costs, how much NCCL is owed by CMEC for historic development costs that NCCL have put in. Previously, this was assessed at $17million (when we were working with SEP as opposed to CMEC), but we have spent more since then (and now working with CMEC). Add to that this was for the Power Plant, not including the mine. The total project is Power Plant and Coal Mine. Hanno has said that the more up to date figures will be $17m to $25m. Well we know it can't be $17m. It will be, in my view, towards the very top of that range (I have sneaky suspicion it could be more).So, in the space of the coming weeks, we get confirmation of stakes and a firm formal commitment to the project, of/ by partners, and we begin to have some concrete numbers for helping to value the company.Add to that our 40% stake (currently plans, may change, all good whichever way); and developer's premium/ fee, which will perhaps in the order 2 x Historic Costs, which we learn down the road. We looking at a company valuation many times more than where we are, all kicking off soon.

Hi DeltaFox, all profit in an ISA is tax-free, the £20K refers to the maximum you can add as new money to an ISA each year, it has nothing to do with profits. If your £20K becomes £60K you can withdraw it all without paying any tax. No brainer!

I have used HL twice to Bed & ISA and been pleased and relieved each time that it worked out well! I held off for a while as both shares were rising quickly and I did not want to lose out while I was out of the market. However, on each occasion the transfer took place quickly and I only ‘lost’ about 5000 shares out of about 1 million each time. If you are planning to stay invested then moving as much as you can is well worth it as your gains, assuming there are some, in a tax-free ISA account will obviously not attract CGT. Remember that the more you make the more CGT you will pay so a little bit of pain now while you get what you can into the shelter of an ISA will prove to be a very sensible decision. Good luck with your investing career!

Not sure what is wrong with HL ‘live prices’ which has shown 178/182 for at least an hour while a dummy buy shows offer prices varying from 180 to 183 - anyone else got the same issue.

Very promising momentum at the moment as we await BAMS and LRT announcements, as well as regular news of other developments, perhaps further manufacturing and logistics partners. However, what I am really waiting for is the public naming of the company as the manufacturer of the gold-standard antigen test - that will put the seal of approval on Alastair's company's work on the test and move Avacta into a completely different league. I am very much a long-term holder.

And have just taken a little bit more from Syme to buy a further 13743 at 5.05

Clear momentum now so decided to pay 5.14 for another 31985 shares - have been buy for almost 4 years and at long last the market is beginning to catch up with NCCL's amazing project. Lots of LTHs have been waiting here for a long time and for newcomers this is a great time to research one of AIM's hidden gems.

At CF73's request I have copied a link below to a document from the file which was first highlighted earlier today by hammerphil1989. When you open all the documents have a look at the names of the delegates at the pre-bid meeting and you will see the CMEC representative listed - his name is Deng Yuren and he is No 35 on the list! I cannot find any other reference to him in the later papers, although I scanned more than I read (!), so I am assuming he was there as an interested observer, possibly and perhaps probably because of the link between the transmission line and our partnership project with CMEC. Very intriguing!

https://drive.google.com/drive/folders/1xuSv8Hr052Hma5yLIR_zMiruOPvkukaE

Great detective work this morning, CF73 et al, everything is falling into place quietly, reinforcing the magnitude of the project and its important to the region, to the country and to surrounding countries. Confirmation of CMEC's involvement, for whatever reason but most likely because of its partnership at Tete with NCCL, is a very interesting little piece of news. Were they representing the consortium, are they soon to be the lead partners, are they soon to own the whole project? No idea but worth thinking about as a possibility.

Fantastic news for two reasons - further confirmation of the medical value of Affirmer technology from a major partner and proof that AVCT is a seriously cash-generative company which is developing a world-leading antigen test as just one of its several work streams. The more I learn the more I believe this is a company which will remain a core holding for me for a considerable time.

Another promising step forward with this further collaborative agreement with a major US institution. MXCT is definitely one to watch and I will gradually expand my holding.

Now that is really interesting news! I am sure that a very large company like CMEC, just like BP and others, realises that it needs to diversify its interests for all sorts of reasons, including commercial and public perception. The fact that they have announced an energy storage partnership could be of great interest to NCCL shareholders as NCCL has already set up an energy storage partnership with GridX which gives them first refusal rights to invest in a whole series of planned renewable energy projects across Mozambique.
There has been plenty of discussion here about the possibility of CMEC buying NCCL at Financial Closure of the Tete project in 2021 or perhaps even earlier. Does today's announcement make a takeover bid even more likely given that they could conceivably include NCCL's agreement with GridX in their bid and perhaps install Hanno as the CEO? I have no evidence whatever for this but for those of us who know the NCCL story and are LTHs it is perhaps an interesting speculation.

Thank you, Maltby, for this very clear and correct interpretation. It is always better to work from original sources and the best we have is what appeared, and was later altered, on the Medusa site. The Medusa Life Science test is an antibody test, it will not be in competition with Avacta's antigen test and, if we trust Alistair Smith and his team as most of us clearly do, I am more than happy to back the distribution deals he strikes for a therapy which means far more to him than it can ever to do us. The company is his life whereas to us it is an investment opportunity which we can take or leave as we like. I would never back a company whose leadership I was not happy to trust but, from the outside looking in, everything I have seen and read sits well with me. That is why the timing of THE big RNS is not of any concern - I know nothing about scientific research but I do understand timescales when it comes to the importance of accuracy and reliability of data and I am happy to wait for as long as it takes the team to validate and publish the data.

A very interesting article today in the Telegraph which emphasises just how important it is that the accuracy of antigen testing results should be as close to 100% as possible. There is clearly little confidence that what is available to date is telling the true story so the closer AVCT can get to 100% the better. https://www.telegraph.co.uk/news/2020/08/12/statistical-quirk-means-coronavirus-pandemic-may-never-officially

If you have recently come across NCCL for whatever reason I suggest you spend some time researching what investors on this board and in Twitter groups consider to be among the best hidden gems on AIM. There are no rampers or derampers on the board, just very well-researched and committed long-term holders who are gradually increasing in number as we approach the end-game. I will not try to explain what NCCL is all about - even a cursory read of the posts on this board will whet your appetite and encourage you to do your own research, starting with the RNSs.
Now time for a confession - none of us know why it has taken so long for the shareprice to reflect the fantastic prospects of NCCL and it is only fair to come clean and say that many of NCCL's most knowledgeable supporters have averages of about 6.00p. I certainly do and I own almost 2 million shares! I am frustrated but 100% confident in my investment and only mildly jealous of those who are investing for the first time at such crazy prices!
Having admitted I and others are well down at the moment it would be reasonable for new readers simply to conclude that this is a desperate ramp! I have invested for many years and know a ramp when I see one. I trust that a quick skim through my posts, and those of several others, will reassure you that we are not rampers but intelligent investors desperate for NCCL to appear on the radars of other investors who, in my personal view (and it is of course just my personal view and not advice of any kind!) stand to make a significant profit if they decide to invest. The window of opportunity, which many of us have watched sitting stubbornly open for far too long without ever considering selling, is now hopefully closing fast. I topped up again twice in the past two weeks and will no doubt keep doing so while I can at these prices!

Agreed, Chrishutch, this in my eyes is one of the few hidden gems on AIM. NCCL is developing a power station and mine complex which is an integral part of the Mozambiquan government's 25 year plan for the electrification of the country. It appears in official documentation as a 'done' deal and in the last couple of days plans were announced to select a contractor to develop the electricity transmission line from NW Mozambique, where only one new power station is to be built (NCCL in Tete province). Why would this line be needed if the power station and mine complex were not part of the masterplan? And of course we are backed by two majors, CMEC and GE. CMEC are about to become significant equity partners which will confirm their long-term commitment following their initial signing of a joint JDA with NCCL and GE. And if that is not enough the project has the active backing of the governments of both China and Mozambique and has been declared by them as a priority project.
NCCL is worth so much more than its current market value and I will continue to add while we are still able to buy at what will soon be seen as a stupid price!

I don’t agree that there might be a negative response - I am really pleased to see the company continues its work across all its platforms and is not in danger of being seen as a one-trick pony. Avacta is becoming a more attractive long-term investment opportunity by the week and it is good to have a normally cautious biotech CEO talking about Neil’ s appointment helping the company ‘to realise the enormous potential of the group’.

It is good to read more and more comments here reflecting the importance of gold-standard quality over perceived ‘first-mover’ advantage. Increasing numbers of examples of ineffective and potentially dangerous tests are coming to light while all the time the need for accurate and reliable testing on a massive scale grows worldwide. Alastair Smith and his team are clearly focussed solely on the provision of an antigen test which will stand up to intense scrutiny and meet a very serious need. They are making significant progress in the areas of optimisation, plans for validation, development of public and private relationships, manufacturing and distribution and they are keeping investors informed at every step. This is just what I want to see as an investor as opposed to a trader, particularly as the development of an antigen test for Covid-19 is only one of an array of projects on which they are working.

On reflection I am not sure that my analogy of the tortoise and the hare is the correct one - the Avacta tortoise must be on speed to have reached the stage it is at so quickly in scientific R&D terms! I hate to think what all the hares are on but some seem to have cut one too many corners in their desire to win the race and my money, and my investment, remains firmly on our Super Tortoise!

Excellent work today, CF73, thank you for drawing the different threads together - all gradually coming together as you rightly point out.

I agree that the logic is a little bit unusual but I believe that the announcement has been made as a gentle reminder to the government, to other official bodies, to fellow-researchers and to investors that everything is on track and that the potential scale and value of what they are doing will be worth the wait! He wants everyone to know that patience is needed and that it will be rewarded in different ways for different interest groups.
It has been said so often, but is worth repeating, that scientific research takes as long as it takes and accuracy and reliability, not to mention efficacy and safety, matter more than short-term financial considerations. As it is Avacta, and many other companies in the field, have already compressed their timeframes to an incredible degree which must be exhausting for everyone involved. What is being achieved in the field of Covid-19 and related diseases is quite extraordinary and I am not at all surprised that Dr Al has somewhat unusually used the public forum of an RNS to praise and thank his colleagues. He has also of course ensured that they are shareholders. His labs must be incredibly exciting and challenging places to be at the moment. They will be working flat out and I cannot imagine anyone is thinking of air bridges or even staycations!